Review Article
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Table 1
Table of HDACs inhibitors discussed in this paper, organized by class (refer to text for references).
| HDACs inhibitor class | HDACs inhibitors | Other common identifiers | Clinical trial phase | Structure |
| Small molecular weight carboxylates | Valprioc acid | Depakene, Depakote, Depakote ER, Depakote Sprinkle | FDA-approved for epileps, seizures, mania, bipolar disorders, migranes Phase I/II in hematological malignancies and solid tumors | |
| Hydroxamic Acids | Vorinostat | Suberoylanilide hydroxamic acid, (SAHA), Zolinza | FDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors | | Panobinostat | LBH589 | Phase I/II in hematological malignancies and solid tumors | | Belinostat | PXD101 | Phase I/II in hematological malignancies and solid tumors | |
| Benzamides | Entinostat | MS-27-275, MS-275, SNDX-275 | Phase I/II in hematological malignancies and solid tumors | | MGD0103 | Mocetinostat | Phase I/II in hematological malignancies and solid tumors | |
| Cyclic tetrapeptides | Romidepsin | Depsipeptide, Istodax, FK228, FR901228 | FDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors | |
|
|